Yasheng Zhu

State Key Laboratory Of Natural Medicines And Jiangsu Provincial Key Laboratory Of Targetome And Innovative Drugs Medicines
Nanjing, 211198, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Rational Design of Potent and Orally Efficacious PI3Kα/δ Degrader for PIK3CA Mutant Breast Cancer without Hyperglycemic Liability.

Rational Design of Potent and Orally Efficacious PI3Kα/δ Degrader for PIK3CA Mutant Breast Cancer without Hyperglycemic Liability.

Journal: Journal of medicinal chemistry

Published: March 09, 2026

Rational Design of Imidazo[1,2-a]pyridine as an Effective TLR7 Antagonist for the Treatment of Psoriasis: Research Combined with In Silico Study.

Rational Design of Imidazo[1,2-a]pyridine as an Effective TLR7 Antagonist for the Treatment of Psoriasis: Research Combined with In Silico Study.

Journal: Journal of medicinal chemistry

Published: February 18, 2026

Discovery of Novel, Potent, and Selective IRAK1 Inhibitors as Potential Therapeutics for Hepatocellular Carcinoma.

Discovery of Novel, Potent, and Selective IRAK1 Inhibitors as Potential Therapeutics for Hepatocellular Carcinoma.

Journal: Journal of medicinal chemistry

Published: February 04, 2026

Structure-Guided Design of a Highly Selective PI3Kα Inhibitor Overcoming Metabolic Dysregulation with Potent Anti-breast Cancer Efficacy.

Structure-Guided Design of a Highly Selective PI3Kα Inhibitor Overcoming Metabolic Dysregulation with Potent Anti-breast Cancer Efficacy.

Journal: Journal of medicinal chemistry

Published: November 17, 2025

Design, Synthesis, and Activity Evaluation of Novel Nucleosides as ADAR1 Inhibitor for the Treatment of Prostate Cancer.

Design, Synthesis, and Activity Evaluation of Novel Nucleosides as ADAR1 Inhibitor for the Treatment of Prostate Cancer.

Journal: Journal of medicinal chemistry

Published: July 09, 2025

Discovery of a Novel and Potent MET Transcription Inhibitor Targeting Promoter G-Quadruplex for the Treatment of NSCLC.

Discovery of a Novel and Potent MET Transcription Inhibitor Targeting Promoter G-Quadruplex for the Treatment of NSCLC.

Journal: Journal of medicinal chemistry

Published: June 03, 2025

ASO Therapy Targeting STAU2 to Inhibit Pancreatic Ductal Adenocarcinoma Progression and Metastasis by Regulating the PALLD-Mediated EMT Signaling Pathway.

ASO Therapy Targeting STAU2 to Inhibit Pancreatic Ductal Adenocarcinoma Progression and Metastasis by Regulating the PALLD-Mediated EMT Signaling Pathway.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: April 14, 2025

Development of Novel PRMT7 Inhibitors for the Treatment of Prostate Cancer.

Development of Novel PRMT7 Inhibitors for the Treatment of Prostate Cancer.

Journal: Journal of medicinal chemistry

Published: April 14, 2025

Discovery of Novel Small-Molecule Inhibitors Disrupting the MTDH-SND1 Protein-Protein Interaction.

Discovery of Novel Small-Molecule Inhibitors Disrupting the MTDH-SND1 Protein-Protein Interaction.

Journal: Journal of medicinal chemistry

Published: January 10, 2025

ADAR1 is required for acute myeloid leukemia cell survival by modulating post-transcriptional Wnt signaling through impairing miRNA biogenesis.

ADAR1 is required for acute myeloid leukemia cell survival by modulating post-transcriptional Wnt signaling through impairing miRNA biogenesis.

Journal: Leukemia

Published: July 30, 2024

Discovery of Potent and Selective c-Met Degraders for Hepatocellular Carcinoma Treatment.

Discovery of Potent and Selective c-Met Degraders for Hepatocellular Carcinoma Treatment.

Journal: Journal of medicinal chemistry

Published: July 04, 2024

Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting C797S Mutation.

Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting C797S Mutation.

Journal: Journal of medicinal chemistry

Published: April 27, 2024

Showing 1-12 of 19

Last Updated: 09/26/2026